Clinical trials: Cisplatin, completed
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Brain and Central Nervous System Tumors
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085202
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- St. Jude Children's Research Hospital
Non Small Cell Lung Cancer
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy…
- Trial name
- INSPIRE (NCT00982111)
- Testing
- Pemetrexed, Cisplatin, Necitumumab
- Where
- 101 sites in United States, Australia and 18 more
- Volunteers
- 633 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these…
- Trial name
- NCT02777385
- Testing
- Pembrolizumab, Cisplatin, IMRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
- Trial name
- NCT02754726
- Testing
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- HonorHealth Research Institute
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Head and Neck Cancer, Oral Mucositis
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 (IV) when administered in combination with IMRT and cisplatin to up to subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)
- Trial name
- NCT04529850
- Testing
- Drug: GC4419, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 24 sites in Belgium, Czechia and 4 more
- Volunteers
- 38 people
- Sponsor
- Galera Therapeutics, Inc.
Head and Neck Cancer
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
RATIONALE: Radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00052429
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00951496
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 503 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
A Study in Head and Neck Cancer
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus…
- Trial name
- NCT01081041
- Testing
- Cetuximab, Cisplatin, Carboplatin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diffuse Large B-Cell Lymphoma
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory…
- Trial name
- NCT01453205
- Testing
- MEDI-551 2 mg/kg, Rituximab, ICE
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 187 people
- Sponsor
- MedImmune LLC
Non Small Cell Lung Cancer
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin…
- Trial name
- NCT00606021
- Testing
- pemetrexed, Best Supportive Care
- Where
- 5 sites in Egypt, Lebanon and 1 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Carcinoma
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR…
- Trial name
- CheckMate722 (NCT02864251)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 367 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation.
- Trial name
- NCT00580983
- Testing
- IMRT, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Michigan Rogel Cancer Center
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
This phase II trial is studying how well giving bevacizumab together with cisplatin, radiation therapy, and fluorouracil works in treating patients with stage IIB, stage III, stage IVA, or stage IVB nasopharyngeal cancer.
- Conditions
- Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT00408694
- Testing
- 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Cisplatin
- Where
- 108 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00757172
- Testing
- panitumumab, cisplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Limited Stage Small Cell Lung Cancer
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of…
- Trial name
- NCT04952597
- Testing
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 126 people
- Sponsor
- BeiGene